関連する実験動画

Updated: Jun 17, 2026

Encapsulation of Cardiomyocytes in a Fibrin Hydrogel for Cardiac Tissue Engineering
10:18

Encapsulation of Cardiomyocytes in a Fibrin Hydrogel for Cardiac Tissue Engineering

Published on: September 19, 2011

26.2K

導電性ポリマー・ヒドロゲルは,細胞の電気信号伝達をサポートし,心筋梗塞にインプラントされた後の心臓機能を改善します

Anton Mihic1, Zhi Cui1, Jun Wu1

  • 1From Division of Cardiovascular Surgery, Toronto General Research Institute, University Health Network, Ontario, Canada (A.M., Z.C., J.W., G.V., Y.M., S.-H.L. S.L., R.D.W., R.-K.L.); Department of Surgery, Division of Cardiac Surgery, University of Toronto, Ontario, Canada (A.M., Z.C., J.W., G.V., Y.M., S.-H.L. S.L., R.D.W., R.-K.L.); and Department of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan (H.-W.S.).

Circulation
|August 26, 2015
PubMed
まとめ

新しい導電性ポリマーであるポリピロールキトーサンは 心筋梗塞の後の心臓組織の電気伝導を回復します このバイオマテリアルは 心臓の機能を改善し 収縮を同期させ 心臓発作の回復に 役立つ可能性もあります

キーワード:
導電注射用バイオマテリアル心筋梗塞改造する

さらに関連する動画

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

9.4K
Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model09:19

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model

Published on: September 20, 2020

5.0K

関連する概念動画

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...